77072-12-9

Basic information

• Product Name: N-HYDROXY-3-METHOXY-PROPIONAMIDINE
• Synonyms: N'-hydroxy-3-methoxypropanamidine;N'-hydroxy-3-methoxy-propanamidine;(1E)-N'-hydroxy-3-methoxypropanimidamide(SALTDATA: HCl);(1Z)-N'-hydroxy-3-methoxypropanimidamide;MFCD09804778
• CAS NO: 77072-12-9
• Molecular Formula: C₄H₁₀N₂O₂
• Molecular Weight: 118.13
• Mol File: 77072-12-9.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-HYDROXY-3-METHOXY-PROPIONAMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-HYDROXY-3-METHOXY-PROPIONAMIDINE(77072-12-9)
• EPA Substance Registry System: N-HYDROXY-3-METHOXY-PROPIONAMIDINE(77072-12-9)

Safety Data

• Hazardous Substances Data: 77072-12-9(Hazardous Substances Data)

Upstream product

• 110-67-8 3-Methoxypropionitrile 

Downstream Products

• 1035040-78-8 4-[(4-Chlorophenyl)methyl]-2-{[(2R)-1-(2-{3-[2-(methyloxy)ethyl]-1,2,4-oxadiazol-5-yl}ethyl)-2-pyrrolidinyl]methyl}-1(2H)-phthalazinone, trifluoroacetate 
• 1256699-28-1 (3-hydroxyazetidin-1-yl)((3R,5R)-3-(3-(2-methoxyethyl)-1,2,4-oxadiazol-5-yl)-5-(4-(trifluoromethoxy)phenyl)piperidin-1-yl)methanone 
• 1256699-27-0 (3-hydroxyazetidin-1-yl)((3S,5S)-3-(3-(2-methoxyethyl)-1,2,4-oxadiazol-5-yl)-5-(4-(trifluoromethoxy)phenyl)piperidin-1-yl)methanone 

Relevant articles and documents

Discovery of BR102375, a new class of non-TZD PPARγ full agonist for the treatment of type 2 diabetes

As a potential treatment of type 2 diabetes, a novel PPARγ non-TZD full agonist, compound 18 (BR102375) was identified from the original lead BR101549 by the SAR efforts of the labile metabolite control through bioisosteres approach. In vitro assessments

Substituted 3-(1,2,4-Oxadiazol-5-yl)-5-Phenylpiperidines

The invention relates to novel substituted piperidines, to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases

SUBSTITUTED PIPERIDINES

The invention relates to novel substituted piperidines, to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular diseases and tumour diseases.